首页 | 官方网站   微博 | 高级检索  
     


Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors
Authors:Renuka V. Iyer MD  Bhavana Konda MD  MPH  Christos Fountzilas MD  Sarbajit Mukherjee MD  MS  Dwight Owen MD  MS  Kristopher Attwood PhD  Chong Wang MA  Orla Maguire PhD  Hans Minderman PhD  Sheryl-Ann Suffren BA  Karen Hicks BS  John Wilton PhD  Robert Bies PhD  Danielle Casucci BA  Diane Reidy-Lagunes MD  Manisha Shah MD
Affiliation:1. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York;2. Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio;3. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York;4. Flow and Image Cytometry Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, New York;5. Department of Clinical Research Services, Roswell Park Comprehensive Cancer Center, Buffalo, New York;6. Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York;7. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Abstract:
Keywords:angiogenesis  neuroendocrine tumors  nintedanib  serotonin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号